ChristopherSimonHouriganMDDPhil, FRCP

Summary

• Christopher S. Hourigan DM DPhil FRCP is the Director of the Virginia Tech FBRI Cancer Research Center in Washington, DC.
  
  As an oncologist and physician-scientist he has a research focus on approaches to predict the recurrence or development of malignancy. He chairs the national prospective clinical protocol to validate measurable residual disease testing (MRD) in acute myeloid leukemia (AML) (NCT05224661), is co-PI of the FNIH Biomarkers Consortium MRD in AML Project, and co-chair of NGS for the European Leukemia Network AML MRD clinical guidelines.
  
  Dr. Hourigan received medical and research doctorates from Oxford University and completed residency and oncology fellowship training at Johns Hopkins School of Medicine where he was subsequently a practicing physician on the inpatient acute leukemia service and faculty member. He was previously a tenured Senior Investigator, co-director of the Myeloid Malignancies Program, and Chief of the Laboratory of Myeloid Malignancies at the National Institutes of Health. Dr. Hourigan is board certified in medical oncology and hematology.